Neurotrophic Factors: The Growth Signals of the Brain
The adult brain is not static. Neurons form new connections, strengthen existing ones, and prune inactive synapses throughout life — a process collectively termed neuroplasticity. At the molecular level, neuroplasticity depends on neurotrophic factors: signaling proteins that support neuronal survival, growth, and synaptic remodeling.
Two neurotrophic factors dominate cognitive research: brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Several research peptides — notably Semax, Selank, and Dihexa — have been studied for their effects on these neurotrophic pathways.
BDNF and NGF: The Core Neurotrophic Pathways
Brain-Derived Neurotrophic Factor (BDNF)
BDNF is the most abundant neurotrophin in the adult brain. It signals through the TrkB receptor (tropomyosin receptor kinase B), activating intracellular cascades including:
- PI3K/Akt pathway: Promotes neuronal survival and resistance to apoptosis
- MAPK/ERK pathway: Drives gene expression related to synaptic plasticity and memory consolidation
- PLCγ pathway: Modulates intracellular calcium and synaptic transmission
BDNF plays a central role in long-term potentiation (LTP), the cellular mechanism underlying learning and memory. Reduced BDNF levels have been associated with cognitive decline in aging, neurodegenerative conditions, and mood disorders in published research (Binder and Scharfman, 2004).
Nerve Growth Factor (NGF)
NGF was the first neurotrophic factor discovered, earning Rita Levi-Montalcini the 1986 Nobel Prize. NGF signals through the TrkA receptor and is particularly important for cholinergic neurons in the basal forebrain — the population most severely affected in Alzheimer's disease research models.
While BDNF is broadly distributed across the brain, NGF's role is more focused on specific neuronal populations. This complementary distribution means that compounds affecting BDNF and NGF modulate different aspects of neural function.
Semax: The ACTH Fragment Neuropeptide
Background
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) based on the ACTH(4-10) fragment, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. The C-terminal Pro-Gly-Pro tripeptide extension was added to improve metabolic stability and extend duration of action (Ashmarin et al., 1995).
Neurotrophic Research Findings
Dolotov et al. (2006) demonstrated that Semax administration increased BDNF and NGF mRNA expression in the rat hippocampus and cortex. The effect was dose-dependent and persisted for several hours after administration, suggesting transcriptional regulation rather than direct receptor binding.
Agapova et al. (2007) used microarray analysis to examine Semax's effects on gene expression in rat brain tissue. The study identified upregulation of genes involved in:
- Neurotrophic factor signaling (BDNF, NGF, GDNF pathways)
- Immune modulation (cytokine regulation, chemokine expression)
- Oxidative stress response (antioxidant enzyme expression)
- Synaptic plasticity (glutamate receptor subunit expression)
Cognitive and Neuroprotective Research
Levitskaya et al. (2004) published research examining Semax in rodent models of cerebral ischemia. The study reported reduced infarct volume and improved neurological scores in Semax-treated animals compared to controls. The proposed mechanism involved both neurotrophic factor upregulation and direct neuroprotective effects through modulation of apoptotic pathways.
In cognitive testing paradigms, Semax has been studied using the Morris water maze, passive avoidance, and object recognition tasks. Glazova et al. (2005) reported improved performance in learning and memory tasks in both normal rats and rats with experimentally induced cognitive deficits.
Selank: The Tuftsin Analog
Background
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic analog of the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), extended with the same Pro-Gly-Pro stabilizing sequence used in Semax. It was developed at the same Russian research institute and is often studied alongside Semax due to their shared structural features (Kozlovskii and Danchev, 2003).
Anxiolytic and Cognitive Research
Selank's research profile centers on anxiolytic effects coupled with cognitive modulation — a combination that distinguishes it from classical anxiolytic compounds (benzodiazepines), which typically impair cognition.
Seredenin et al. (2001) demonstrated that Selank produced anxiolytic effects in the elevated plus maze test without sedation or motor impairment. Subsequent research by Kozlovskaya et al. (2003) showed that Selank's anxiolytic effects were associated with modulation of GABA-A receptor function, specifically through changes in benzodiazepine binding site sensitivity.
Enkephalin Metabolism
Zolotarev et al. (2006) published research showing that Selank inhibits enkephalin-degrading enzymes, thereby increasing endogenous enkephalin levels. Since enkephalins are endogenous opioid peptides involved in mood regulation and pain modulation, this mechanism may contribute to Selank's observed anxiolytic profile. Unlike exogenous opioid compounds, this indirect modulation does not appear to produce tolerance or dependence in the published animal studies.
Dihexa: The HGF Pathway Modulator
Background
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) was developed by Joseph Harding and colleagues at Washington State University. It is a modified hexapeptide derived from angiotensin IV, designed to interact with the hepatocyte growth factor (HGF)/c-Met receptor system in the brain (McCoy et al., 2013).
HGF/c-Met Signaling in the Brain
Hepatocyte growth factor, despite its name, is active in the brain and functions as a neurotrophic factor. HGF binds the c-Met receptor, activating downstream pathways that promote:
- Dendritic spine formation and stabilization
- Synaptogenesis (formation of new synaptic connections)
- Neuronal survival through anti-apoptotic signaling
- Neurite outgrowth and axonal guidance
Research Findings
McCoy et al. (2013) published research in the Journal of Pharmacology and Experimental Therapeutics demonstrating that Dihexa enhanced cognitive performance in scopolamine-induced amnesia models in rats. The study reported that Dihexa was active at picomolar concentrations — orders of magnitude more potent than BDNF in promoting synaptogenesis in cell culture assays.
Benoist et al. (2014) extended these findings to aged rats, showing improved spatial memory in the radial arm maze and Barnes maze following Dihexa administration. Histological analysis revealed increased dendritic spine density in the hippocampus of treated animals.
Comparing Neuropeptide Approaches
These three neuropeptides target cognitive function through different mechanisms:
- Semax: Broad neurotrophic factor upregulation (BDNF, NGF), immune modulation, ACTH-derived
- Selank: GABA-A modulation, enkephalin metabolism, tuftsin-derived anxiolytic profile
- Dihexa: HGF/c-Met synaptogenic signaling, angiotensin IV-derived, picomolar potency
The diversity of mechanisms reflects the complexity of cognitive function itself. Memory, attention, anxiety regulation, and neuroprotection involve overlapping but distinct neural circuits and molecular pathways, and researchers often study these peptides in combination to examine potential synergistic or complementary effects.
This article is for educational and informational purposes only. BeaCapra supplies research peptides for laboratory and research use. Nothing in this article constitutes medical advice.